Lutrate 1 month Depot 3.75 mg powder and solvent for prolonged-release suspension for injection
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Patient Information leaflet
(PIL)
12-09-2015
Summary of Product characteristics
(SPC)
17-04-2019
Active ingredient:
LEUPRORELIN ACETATE
Available from:
Mercury Pharmaceuticals Ltd
ATC code:
L02AE; L02AE02
INN (International Name):
LEUPRORELIN ACETATE
Dosage:
3.75 milligram(s)
Pharmaceutical form:
Powder and solvent for suspension for injection
Administration route:
intramuscular route
Units in package:
One (1) type I glass vial containing 3.75 mg
Prescription type:
Product subject to prescription which may not be renewed (A)
Manufactured by:
GP-Pharm S.A.
Therapeutic group:
Endocrine therapy. Hormones and related agents. Gonadotropin-releasing hormones analogues
Therapeutic area:
Gonadotropin releasing hormone analogues; leuprorelin
Therapeutic indications:
It is indicated for palliative treatment of locally advanced or metastatic prostate cancer
Authorization status:
Not marketed
Authorization date:
2015-07-17
Summary of Product characteristics
Health Products Regulatory Authority
16 April 2019
CRN008YR9
Page 1 of 11
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Lutrate 1 month Depot 3.75 mg powder and solvent for prolonged-release
suspension for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 3.75 mg of leuprorelin acetate (equivalent to 3.57
mg leuprorelin free base).
1 ml of reconstituted suspension contains 1.875 mg of leuprorelin
acetate.
Excipients with known effect:
Each vial contains from 1.3 to 2.2 mg (<1 mmol) of sodium (as
carmellose sodium).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder and solvent for prolonged-release suspension for injection.
Powder: white to off-white powder.
Solvent: clear transparent solution (pH 5.0 – 7.0).
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
(i) Metastatic prostate cancer.
(ii) Locally advanced prostate cancer, as an alternative to surgical
castration.
(iii) As an adjuvant treatment to radiotherapy in patients with
high-risk localised or locally advanced prostate cancer.
(iv) As an adjuvant treatment to radical prostatectomy in patients
with locally advanced prostate cancer at high risk of disease
progression.
(v) As neo-adjuvant treatment prior to radiotherapy in patients with
high-risk localised or locally advanced prostate cancer.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The usual recommended dose of Lutrate 1 month Depot is 3.75 mg
presented as a one month depot injection and
administered as a single intramuscular injection every month.
Lutrate 1 month Depot must be administered under the supervision of a
physician or a qualified health practitioner.
The dose of Lutrate 1 month Depot allowing the continuous release of
leuprorelin acetate during one month is incorporated in
a depot formulation. The lyophilized powder should be reconstituted
and administered as a single intramuscular injection at
monthly intervals. Intra-arterial or intravenous administration must
be avoided. The vial of Lutrate 1 month Depot mi
Read the complete document
